進行がん患者における抗PD-L1抗体の安全性と活性

Brahmerら（Thu,）がこの問題を研究した。

www.synapsesocial.com/papers/69d781803fae90fd6048f8ee — DOI: https://doi.org/10.1056/nejmoa1200694

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer· 2012 · 12,592 citations
2. The blockade of immune checkpoints in cancer immunotherapy· 2012 · 13,660 citations
3. Toxicity and response criteria of the Eastern Cooperative Oncology Group· 1982 · 11,558 citations
4. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion· 1999 · 2,475 citations
5. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4· 1995 · 2,889 citations